JPM vs OXSQ
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
OXSQ exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9, indicating a near-total failure of fundamental health metrics. The company's dividend profile is unsustainable, with a payout ratio of 466.67% and a yield of 22.46% that likely erodes capital. Negative profit margins (-46.43%) and a bearish technical trend (0/100) further underscore a deteriorating operational state. With a target price of $1.75 sitting below the current market price, there is little fundamental support for current valuation levels.
Compare Another Pair
Related Comparisons
JPM vs OXSQ: Head-to-Head Comparison
This page compares JPMorgan Chase & Co. (JPM) and Oxford Square Capital Corp. (OXSQ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.